Stock Events

Stock Events

CANTARGIA AB 

€0.138000
0
-€0.00-1.92%Friday 19:17

Statistics

Day High
0.1414
Day Low
0.1362
52W High
0.587
52W Low
0.094
Volume
-
Avg. Volume
-
Mkt Cap
34.31M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 25Expected
Q4 2025
Q1 2026
Q2 2026
Next
-0.02
-0.02
-0.01
-0.01
Expected EPS
-0.014286608
Actual EPS
N/A

Financials

-12,274.65%Profit Margin
Unprofitable
2021
2022
2023
2024
2025
2026
24,695.35Revenue
-3.03MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals, Inc. is known for its development of monoclonal antibodies for cancer and other diseases, making it a competitor in the biotechnological approach to cancer treatment.
Incyte
INCY
Mkt Cap24.54B
Incyte Corporation works on the discovery, development, and commercialization of proprietary therapeutics, including for cancer, competing in the same market as Cantargia.
Merck
MRK
Mkt Cap368.89B
Merck & Co., Inc. has a broad portfolio of cancer treatments, including immunotherapy products, competing with Cantargia's cancer focus.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol-Myers Squibb Company offers a range of cancer treatments, including antibody therapies, making it a direct competitor.
AMGEN
AMGN
Mkt Cap251.94B
Amgen Inc. develops innovative human therapeutics, including for cancer, with a focus on biologic medicines that compete with Cantargia's offerings.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, Inc. is engaged in the research, development, and commercialization of innovative medicines in areas including oncology, competing with Cantargia's cancer therapies.

About

Cantargia AB (publ), a biotechnology company established in Lund, Sweden, in 2010, is dedicated to the research and development of antibody-driven therapies for severe illnesses. Its lead product, CAN04, is an antibody specifically engineered to target Interleukin-1 Receptor Accessory Protein (IL1RAP). This innovative treatment aims to identify and stimulate the immune system to destroy cancer cells, while also mitigating tumor-related inflammation fueled by the Interleukin-1 system, and is currently in Phase IIa clinical trials. The company is also advancing CAN10, another IL1RAP-specific antibody, through preclinical development for autoimmune and inflammatory conditions like systemic sclerosis and myocarditis. Additionally, Cantargia is exploring other CANxx antibodies that also interact with IL1RAP. The manufacturing and production of CAN04 are facilitated through partnerships with Patheon Biologics BV and BioWa Inc., and its clinical study is supported by Specialized Medical Services-oncology BV.
Show More
CEO
Hilde Hermansen Steineger
Employees
22
Country
Sweden
ISIN
SE0006371126
WKN
000A2JAZX

Listings

STU
DE
7V3.STU
MU
DE
7V3.MU
ST
SE
CANTA.ST
F
DE
7V3.F

0 Comments

Share your thoughts

FAQs

What is CANTARGIA AB stock price today?▼
The current price of 7V3.STU is €0.14 EUR — it has decreased by -1.92% in the past 24 hours. Watch CANTARGIA AB stock price performance more closely on the chart.
What is CANTARGIA AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange CANTARGIA AB stocks are traded under the ticker 7V3.STU.
Is CANTARGIA AB stock price growing?▼
7V3.STU stock has fallen by -0.43% compared to the previous week, the month change is a +23.55% rise, over the last year CANTARGIA AB has showed a -48.12% decrease.
What is CANTARGIA AB market cap?▼
Today CANTARGIA AB has the market capitalization of 34.31M
When is the next CANTARGIA AB earnings date?▼
CANTARGIA AB is going to release the next earnings report on November 25, 2026.
What were CANTARGIA AB earnings last quarter?▼
7V3.STU earnings for the last quarter are -0.01 EUR per share, whereas the estimation was -0.01 EUR resulting in a +23.53% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is CANTARGIA AB revenue for the last year?▼
CANTARGIA AB revenue for the last year amounts to 24,695.35 EUR.
What is CANTARGIA AB net income for the last year?▼
7V3.STU net income for the last year is -3.03M EUR.
How many employees does CANTARGIA AB have?▼
As of November 8, 2026, the company has 22 employees.
In which sector is CANTARGIA AB located?▼
CANTARGIA AB operates in the Health & Wellness sector.
When did CANTARGIA AB complete a stock split?▼
CANTARGIA AB has not had any recent stock splits.
Where is CANTARGIA AB headquartered?▼
CANTARGIA AB is headquartered in Lund, Sweden.